PTAB designates seven IPR decisions as “informative”

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

PTAB designates seven IPR decisions as “informative”

ptab-web-icon.jpg

The Patent Trial and Appeal Board has designated seven of its decisions rendered in inter partes review (IPR) proceedings as “informative”

uspto.jpg

In each decision, the PTAB denied institution of an IPR under 35 USC § 325(d), which permits the Director to take into account whether, and reject the petition or request because, the same or substantially the same prior art or arguments previously were presented.

The seven decisions are:

Medtronic, Inc v Nuvasive Inc., Paper 8, No. IPR2014-00487 (September 11 2014)

Unified Patents Inc v PersonalWeb Techs., LLC, Paper 13, No. IPR2014-00702 (July 24 2014)

Prism Pharma Co v Choongwae Pharma Corp., Paper 14, No. IPR2014-00315 (July 8 2014)

Unilever, Inc v Procter & Gamble Co., Paper 17, No. IPR2014-00506 (July 7 2014)

Medtronic, Inc v Robert Bosch Healthcare Systems, Inc., Paper 17, No. IPR2014-00436 (June 19 2014)

Intelligent Bio-Systems Inc. v Illumina Cambridge Limited, Paper 19, No. IPR2013-00324 (November 21 2013)

ZTE Corp v ContentGuard Holdings, Inc., Paper 12, No. IPR2013-00454 (25 September 25 2013)

Decisions designated as "informative" can be viewed here.


more from across site and SHARED ros bottom lb

More from across our site

VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Matteo Di Lernia, advocate at LCA Studio Legale, unpicks the CJEU’s ruling in M.M. Ristorazione v Villa Ramazzini, including its impact on litigation strategies
Gift this article